無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

細胞治療薬製造市場

Cell Therapy Manufacturing Market (2nd Edition), 2018-2030

発行 ROOTS ANALYSIS 商品コード 462554
出版日 ページ情報 英文 444 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
細胞治療薬製造市場 Cell Therapy Manufacturing Market (2nd Edition), 2018-2030
出版日: 2018年07月11日 ページ情報: 英文 444 Pages
概要

細胞治療薬製造市場は、既存の製造設備の拡張や新規の専用施設の建設によって、中・長期的に安定成長が続くと予測されています。技術的な進歩が、成長の主な成功要因になります。

当レポートでは、細胞治療薬製造市場について調査分析し、現在の市場情勢と将来の見通しについて、体系的な情報を提供しています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 市場概要

  • 概要
  • 総合市場情勢
  • 物流サービスプロバイダーの役割

第5章 ロードマップ:既存の課題を克服する潜在的な戦略

  • 概要
  • 米国のロードマップ
  • その他の地域のロードマップ

第6章 細胞治療薬製造:インハウスメーカー

  • 概要
  • Argos Therapeutics
  • Bavarian Nordic
  • Cytori Therapeutics
  • Juno Therapeutics
  • MEDIPOST
  • SOTIO
  • Stemedica Cell Technologies

第7章 細胞治療薬製造:業界企業

  • 概要
  • Cell and Gene Therapy Catapult
  • CELLforCURE
  • Lonza
  • PharmaCell
  • PCT
  • Roslin Cell Therapies
  • Waisman Biomanufacturing

第8章 細胞治療薬製造:業界外企業

  • 概要
  • Center for Cell and Gene Therapy, Baylor College of Medicine (米国)
  • Centre for Cell Manufacturing Ireland, National University of Ireland (アイルランド)
  • Clinical Cell and Vaccine Production Facility, University of Pennsylvania (米国)
  • Guy's And St. Thomas' GMP Facility, Guy's Hospital (英国)
  • Newcastle Cellular Therapies Facility, Newcastle University (英国)
  • Rayne Cell Therapy Suite, King's College London (英国)
  • Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre of Regenerative Medicine (英国)
  • Laboratory of Cell and Gene Medicine, Stanford University (米国)

第9章 NPOの役割

  • 概要
  • NPOのリスト
  • 国際団体

第10章 最近の発展

  • 概要
  • 提携/契約モデル
  • 提携のリスト
  • パートナーシップ分析

第11章 市場規模と予測

  • 状況と背景
  • 予測手法
  • 細胞治療薬製造市場
  • 地域別分析

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 結論

第14章 調査分析

第15章 インタビュー

第16章 付録1

第17章 付録2

目次
Product Code: RA100112

The use of live cells for therapeutic purposes can be traced back to 1968, when patients were first successfully treated with allogeneic human hematopoietic stem cell transplants. This practice has now become an integral part of clinical procedures in the space of bone marrow regeneration and organ transplantation. Cell-based therapies are an emerging segment of the overall biopharmaceutical industry. Post the approval of first cell-based therapy, Carticel®, in 1997 in the US, the field has rapidly advanced and a number of such therapies are currently under development. Given the personalized nature of these treatment options, they are highly specific and hold the potential to address unmet medical needs associated with the treatment of several disorders. The promising therapeutic potential has led many pharmaceutical companies and investors to put in a significant amount of capital towards the development and commercialization of these therapies.

Popular examples of approved cell-based therapies include (in order of their year of approval) Carticel®, CreaVax-RCC®, JACE, ReliNethra, PROVENGE® and Prochymal®. In addition, over 500 cell-based therapy candidates are currently in different stages of clinical development; these are being evaluated in over 1,000 active clinical studies in various regions across the globe. The growing number of cell therapy candidates, coupled with their rapid progression through the various phases of clinical development, continues to create an increasing demand for facilities that offer manufacturing services for these therapies. The market already has a wide array of well-established players, mid-sized companies and start-ups. Several industry players as well as academic institutes are significantly contributing to the production of GMP grade cell types. In addition, the market has witnessed the entry of several players that offer novel technology solutions, aimed at improving and upgrading existing cell-based therapies and their manufacturing processes. We have observed that such players have signed multiple partnerships / collaborations with an aim to optimize, scale-up and expand the capabilities for production of cell-based therapies.

Looking at the evolutionary trends, we believe that the cell therapy manufacturing market will continue to be steadily driven in the mid to long term by expansion of existing manufacturing facilities and establishment of new dedicated facilities. Technological advancements to mitigate challenges posed by conventional methods of production will act as a key enabler to this growth.

Synopsis

The "Cell Therapy Manufacturing Market, 2017-2027" report provides an extensive study of the rapidly growing market of cell therapy manufacturing and focuses both on contract manufacturers and cell therapy developers with in-house manufacturing facilities. These therapies are anticipated to emerge as viable alternatives to conventional treatment options. The scope of this report primarily includes manufacturing of advanced therapy medicinal products (ATMPs) that involve the use of immune cells such as T-cells, Tregs, dendritic cells, tumor cells and NK cells, and stem cells such as adult stem cells, human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).

Several players, including cell therapy developers, research institutes, contract manufacturing organizations, and government and non-profit organizations, are playing a critical role in the development and manufacturing of these cell therapies. In fact, a number of these players have made heavy investments to expand their existing capabilities and establish new facilities for cell therapy products in order to meet the increasing demand. Additionally, stakeholders have received significant support from governments worldwide, in terms of funding and establishment of consortiums to accelerate the transition of these therapies from laboratories to clinics. It is important to highlight that companies that offer logistics and operational services have developed systems / tools for safer and quicker delivery of therapies from manufacturing sites to patients; this has been identified as one of the key challenges in the overall development process.

During the course of our study, we identified over 110 organizations that are actively involved in the manufacturing of cell therapies. In addition to other elements, the study provides information on:

  • The current status of the market with respect to key players along with information on the location of their manufacturing facilities, scale of production, type of cells manufactured, purpose of production (fulfilling in-house requirements / as a contract service provider) and the type of organization (industry / non-industry).
  • Most active regions in terms of cell therapy manufacturing with schematic representations of world maps that clearly highlight the global cell therapy manufacturing hubs.
  • Roadmaps published by different agencies across the globe to provide strategies to advance cell therapy manufacturing.
  • Elaborate profiles of key players that offer contract manufacturing services (industry and non-industry) or manufacture cell therapies in-house; each profile covers an overview of the company, information on its manufacturing facilities, and recent collaborations.
  • Partnerships that have taken place in the recent past covering manufacturing and services agreements, agreements specific to technology / instruments / process developments, and mergers and acquisitions.
  • A discussion on the key enablers of the market and challenges associated with the cell therapy manufacturing process.
  • Potential future growth of the cell therapy manufacturing market segmented by the type of cell therapy, source of cells (autologous and allogeneic) and purpose of manufacturing (in-house and contract services). For the purposes of our analysis, we took into consideration several parameters that are likely to impact the growth of this market over the next decade; these include the likely increase in number of clinical studies, patient population, anticipated adoption of commercial cell-therapies and expected variation in manufacturing costs.

We have provided an estimate of the size of the market in the short to mid-term and long term for the period 2017 to 2027. The base year for the report is 2016. To account for the uncertainties associated with the development of novel therapeutics and to add robustness to our model, we have provided three forecast scenarios portraying the conservative, base, and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 100 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Tim Oldham (CEO, Cell Therapies), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi), Dr. Gerard J Bos (CEO, CiMaas).

Example Highlights

  • 1. Overall, we identified over 60 industry players and 50 academic institutes / non-profit organizations that are actively contributing in the field of cell-therapy manufacturing. We came across 68 players that are involved in manufacturing of immunotherapies and 66 players that possess capabilities for manufacturing adult stem cell therapies. Further, 28 organizations have facilities for both immunotherapies and adult stem cell therapies. Within the stem cell therapy market, we identified 15 and 17 organizations that are involved in the manufacturing of ESCs and iPSCs, respectively.
  • 2. As majority of cell therapy products are in early phase of development, several manufacturers have facilities that meet the clinical scale production requirements. However, some players (31, as per our research) have developed / are developing commercial scale capacity for cell therapy production. Examples include (in alphabetical order) apceth Biopharma, Brammer Bio, Cell and Gene Therapy Catapult, CELLforCURE, Cognate BioServices, EUFETS, Guy's and St Thomas' Facility, Lonza, MaSTherCell, PharmaCell and WuXi AppTec.
  • 3. Although the current market landscape is dominated by contract manufacturers, some well-established cell therapy developers have set up in-house manufacturing capabilities to support their requirements of cGMP grade cells. Examples include (in alphabetical order) Adaptimmune, Argos Therapeutics, Cell Medica, Cellular Biomedicine Group, Juno Therapeutics, Kite Pharma and SOTIO. In addition, we identified over 10 organizations that manufacture cell-based therapies for their own clinical research as well as offer contract services to other organizations Examples include (in alphabetical order) Amsterdam BioTherapeutics Unit (AmBTU), apceth Biopharma, Children's GMP / GMP facility (St. Jude Children's Research Hospital), Cook Myosite, John Goldmann Centre for Cellular Therapy (Imperial College London), MolMed, and PCT (a Caladrius Company).
  • 4. North America has the maximum number of cell therapy manufacturing facilities (~ 43%), followed by the EU where ~40% of the global cell therapy manufacturing facilities are located. Specifically, in the EU, maximum number of manufacturing facilities are located in the UK (~44%). Other emerging pockets for cell therapy manufacturing include Australia, China, Japan, Singapore, South Korea and Israel; facilities in these regions primarily cater to the Asia-Pacific markets.
  • 5. Over 140 collaborations have been inked between cell therapy developers, cell therapy manufacturers and other stakeholders of the industry. The motive behind the partnerships varies; they have been signed for obtaining manufacturing services, gaining access to services related to data management, reagent supply and logistics, upgrading technologies for manufacturing processes, and acquisition of manufacturing facilities.
  • 6. The near-term demand for manufacturing of cell-based therapies will primarily be driven by clinical candidates. In the longer term, the currently approved therapies and late-stage therapies (that are likely to get commercialized in future) will act as key drivers of the market. Our outlook is highly promising; we expect the market for cell therapy manufacturing to grow at an annualized growth rate of ~42% over the course of next ten years and be worth over USD 4 billion in 2027.

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information. The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our report. The summary offers a high level view on the current state of the cell therapy manufacturing market and its likely evolution over the coming decade.

Chapter 3 provides a general introduction to the cell-based therapies and ATMPs, their classification and definitions. It includes a detailed discussion on manufacturing of cell-based therapies, associated challenges, and application of the currently available for cell therapies. The chapter also provides a detailed description on the regulatory landscape for cell therapies.

Chapter 4 identifies the contract service providers / in-house manufacturers that are actively involved in the manufacturing of ATMPs. It provides details on the ATMP manufacturing capabilities of these organizations, specifically focusing on the type of organization, geographic location of their facilities, scale of operation, type of cells manufactured and the purpose of manufacturing (in-house requirement / third party manufacturing). It contains world maps highlighting the geographical locations of cell therapy manufacturing facilities. Further, it discusses the development trends within the overall cell therapy manufacturing landscape.

Chapter 5 provides details on the roadmaps published by different organizations in various geographies, specifically in the US. These roadmaps describe the strategies that are helpful in accelerating the translation from laboratory to clinics.

Chapter 6 contains detailed profiles of in-house manufacturers. Each profile provides a brief overview of the company, its financial performance, details on manufacturing capabilities and facilities, and the relevant collaborations that have been inked over the last few years.

Chapter 7 contains detailed profiles of key industrial contract manufacturers that have clinical and / or commercial scale manufacturing capacities. Each profile provides a brief overview of the company, details on manufacturing capabilities and facilities, and the relevant collaborations that have been inked over the last few years.

Chapter 8 contains detailed profiles of key academic players that offer contract manufacturing services for cell therapies. Each profile provides a brief overview of the organization, and details on manufacturing capabilities and facilities.

Chapter 9 discusses the role of non-profit organizations in advancing cellular therapies. It provides a list of prominent organizations and profiles of key organizations in different regions. Additionally, the chapter provides information of international / national societies that help in disseminating knowledge about the advancement of these therapies in the community.

Chapter 10 features a comprehensive analysis of the collaborations and partnerships that have been forged between the players in this market. It includes a brief description on the various types of partnership models that are employed by stakeholders in this domain. We have categorized the deals / agreements, which have been captured during our research, into different models and have provided analysis on trend of partnerships over time.

Chapter 11 presents a ten year forecast to highlight the likely growth of the cell therapy manufacturing market. We have segregated the financial opportunity by type of cell therapy (T-cell immunotherapy, cell-based cancer vaccines, stem cell therapies and other ATMPs) and the source of cells (autologous and allogeneic). All our predictions are backed by robust analysis of data procured from both secondary and primary sources. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 12 provides a SWOT analysis capturing the key elements and factors that are likely to influence the market's future.

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 14 presents insights from the survey conducted for this study. We invited over 100 stakeholders involved in the development of different types of cell therapies. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 15 is a collection of interview transcripts of the discussions held with key stakeholders in the industry.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. CELL THERAPY MANUFACTURING: INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Cell-based Therapies: Introduction
    • 3.2.1. Cell-based Therapies: A Comparison with Biotechnology Products
    • 3.2.2. Cell-based Therapies: Classification
    • 3.2.3. Cell-based Therapies: Current Market Landscape
  • 3.3. Cell Therapy Manufacturing: An Introduction
  • 3.4. Cell-based Therapies Manufacturing: Key Challenges
  • 3.5. Cell Therapy Manufacturing: Types of Manufacturers
  • 3.6. Cell Therapy Manufacturing: Other Important Considerations
    • 3.6.1. Characterization
    • 3.6.2. Scale-up
    • 3.6.3. Cost of Goods
  • 3.7. Cell Therapy Manufacturing: Regulatory Landscape
    • 3.7.1. Current Scenario
    • 3.7.2. Existing Challenges
    • 3.7.3. Guidelines for Different Development Phases

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Cell Therapy Manufacturing: Overall Market Landscape
    • 4.2.1. Cell Therapy Manufacturing: Distribution by Location of Manufacturing Facility
    • 4.2.2. Cell Therapy Manufacturing: Distribution by Type of Cells
    • 4.2.3. Cell Therapy Manufacturing: Distribution by Purpose of Production
    • 4.2.4. Cell Therapy Manufacturing: Distribution by Scale of Operation
    • 4.2.5. Cell Therapy Manufacturing: Distribution by Source of Cells
  • 4.3. Cell Therapy Manufacturing: Role of Logistic Service Providers

5. ROADMAPS: POTENTIAL STRATEGIES TO OVERCOME EXISTING CHALLENGES

  • 5.1. Chapter Overview
  • 5.2. Roadmap for the United States
    • 5.2.1. Cell Processing
    • 5.2.2. Cell Preservation, Distribution and Handling
    • 5.2.3. Process Monitoring and Quality Control
    • 5.2.4. Standardization and Regulatory Support
    • 5.2.5. Workforce Development
  • 5.3. Roadmaps for Other Geographies
    • 5.3.1. Europe
    • 5.3.2. Asia Pacific

6. CELL THERAPY MANUFACTURING: IN-HOUSE MANUFACTURERS

  • 6.1. Chapter Overview
  • 6.2. Argos Therapeutics
    • 6.2.1. Company Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Product Portfolio
    • 6.2.4. Manufacturing Capabilities
    • 6.2.5. Partnerships / Collaborations
  • 6.3. Bavarian Nordic
    • 6.3.1. Company Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Product Portfolio
    • 6.3.4. Manufacturing Capabilities
  • 6.4. Cytori Therapeutics
    • 6.4.1. Company Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Product Portfolio
    • 6.4.4. Manufacturing Capabilities
    • 6.4.5. Partnerships / Collaborations
  • 6.5. Juno Therapeutics
    • 6.5.1. Company Overview
    • 6.5.2. Financial Overview
    • 6.5.3. Product Portfolio
    • 6.5.4. Manufacturing Capabilities
    • 6.5.5. Partnerships / Collaborations
  • 6.6. MEDIPOST
    • 6.6.1. Company Overview
    • 6.6.2. Financial Overview
    • 6.6.3. Product Portfolio
    • 6.6.4. Manufacturing Capabilities
    • 6.6.5. Partnerships / Collaborations
  • 6.7. SOTIO (Acquired by PPF Group)
    • 6.7.1. Company Overview
    • 6.7.2. Financial Overview
    • 6.7.3. Product Portfolio
    • 6.7.4. Manufacturing Capabilities
    • 6.7.5. Partnerships / Collaborations
  • 6.8. Stemedica Cell Technologies
    • 6.8.1. Chapter Overview
    • 6.8.2. Product Portfolio
    • 6.8.3. Manufacturing Capabilities
    • 6.8.4. Partnerships / Collaborations

7. CELL THERAPY MANUFACTURING: INDUSTRY PLAYERS

  • 7.1. Chapter Overview
  • 7.2. Cell and Gene Therapy Catapult
    • 7.2.1. Company Overview
    • 7.2.2. Service Portfolio
    • 7.2.3. Manufacturing Capabilities
    • 7.2.4. Partnerships/ Collaborations
  • 7.3. CELLforCURE
    • 7.3.1. Company Overview
    • 7.3.2. Service Portfolio
    • 7.3.3. Manufacturing Capabilities
    • 7.3.4. Partnerships/ Collaborations
  • 7.4. Lonza
    • 7.4.1. Company Overview
    • 7.4.2. Service Portfolio
    • 7.4.3. Manufacturing Capabilities
    • 7.4.4. Partnerships/ Collaborations
  • 7.5. PharmaCell
    • 7.5.1. Company Overview
    • 7.5.2. Service Portfolio
    • 7.5.3. Manufacturing Capabilities
    • 7.5.4. Partnerships/ Collaborations
  • 7.6. PCT, a Caladrius Company
    • 7.6.1. Company Overview
    • 7.6.2. Service Portfolio
    • 7.6.3. Manufacturing Capabilities
    • 7.6.4. Partnerships/ Collaborations
  • 7.7. Roslin Cell Therapies
    • 7.7.1. Company Overview
    • 7.7.2. Service Portfolio
    • 7.7.3. Manufacturing Capabilities
    • 7.7.4. Partnerships/ Collaborations
  • 7.8. Waisman Biomanufacturing
    • 7.8.1. Company Overview
    • 7.8.2. Service Portfolio
    • 7.8.3. Manufacturing Capabilities
    • 7.8.4. Partnerships/ Collaborations

8. CELL THERAPY MANUFACTURING: NON-INDUSTRY PLAYERS

  • 8.1. Chapter Overview
  • 8.2. Center for Cell and Gene Therapy, Baylor College of Medicine, US
    • 8.2.1. Overview
    • 8.2.2. Operating Segments
    • 8.2.3. Service Portfolio
    • 8.2.4. Capabilities
  • 8.3. Centre for Cell Manufacturing Ireland, National University of Ireland, Ireland
    • 8.3.1. Overview
    • 8.3.2. Service Portfolio
    • 8.3.3. Capabilities
  • 8.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania, US
    • 8.4.1. Overview
    • 8.4.2. Service Portfolio
    • 8.4.3. Capabilities
  • 8.5. Guy's And St. Thomas' GMP Facility, Guy's Hospital, UK
    • 8.5.1. Overview
    • 8.5.2. Service Portfolio
    • 8.5.3. Capabilities
  • 8.6. Newcastle Cellular Therapies Facility, Newcastle University, UK
    • 8.6.1. Overview
    • 8.6.2. Service Portfolio
    • 8.6.3. Capabilities
  • 8.7. Rayne Cell Therapy Suite, King's College London, UK
    • 8.7.1. Overview
    • 8.7.2. Capabilities
  • 8.8. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre of Regenerative Medicine, UK
    • 8.8.1. Overview
    • 8.8.2. Capabilities
  • 8.9. Laboratory of Cell and Gene Medicine, Stanford University, US
    • 8.9.1. Overview
    • 8.9.2. Capabilities

9. ROLE OF NON-PROFIT ORGANIZATIONS

  • 9.1. Chapter overview
  • 9.2. Cell Therapy Manufacturing: List of Non-Profit Organizations
    • 9.2.1. CellCAN
    • 9.2.2. Cell Therapy Manufacturing Cooperative Research Center
    • 9.2.3. National Cell Manufacturing Consortium
    • 9.2.4. California Institute of Regenerative Medicine
  • 9.3. Cell Therapy Manufacturing: International Societies

10. RECENT DEVELOPMENTS

  • 10.1. Chapter Overview
  • 10.2. Collaboration / Agreement Models
  • 10.3. Cell Therapy Manufacturing: List of Collaborations
  • 10.4. Cell Therapy Manufacturing: Partnership Analysis

11. MARKET SIZING AND FORECAST

  • 11.1. Context and Background
  • 11.2. Forecast Methodology
  • 11.3. Cell Therapy Manufacturing Market, 2017-2027
    • 11.3.1. Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
    • 11.3.2. Cell Therapy Manufacturing Market: Distribution by Source of Cells
    • 11.3.3. Cell Therapy Manufacturing: Distribution by Purpose of Manufacturing
  • 11.4. Cell Therapy Manufacturing Market: Regional View

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Strengths
  • 12.3. Weaknesses
  • 12.4. Opportunities
  • 12.5. Threats

13. CONCLUSION

  • 13.1. A Growing Pipeline of Cell Therapy Products is Likely to Increase the Demand for Manufacturing of Cell-based Therapies
  • 13.2. Stakeholders are Continuously Striving to Overcome Existing Challenges
  • 13.3. Developed Economies have Emerged as Prominent Hubs for Cell Therapy Manufacturing
  • 13.4. Both Industry and Academia have Jointly Led the Initiatives; The Trend is Likely to Persist in the Near Term
  • 13.5. Partnerships / Collaborations have been Widespread and will Continue to act as Key Enablers
  • 13.6. The Manufacturing of Cell-based Therapies is Likely to Become a Multi-billion Dollar Market in the Coming Decade

14. SURVEY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Seniority Level of Respondents
  • 14.3. Type of Cell Therapy
  • 14.4. Scale of Operation
  • 14.5. Source of Cells
  • 14.6. Type of Cell Culture System
  • 14.7. Fill / Finish Service

15. INTERVIEW TRANSCRIPTS

  • 15.1. Chapter Overview
  • 15.2. Tim Oldham, CEO, Cell Therapies
  • 15.3. Brian Dattilo, Manager of Business Development, Waisman Biomanufacturing
  • 15.4. Mathilde Girard, Department Leader, Cell Therapy Innovation and Development, YposKesi
  • 15.5. Dr. Gerard J Bos (CEO, CiMaas)

16. APPENDIX: TABULATED DATA

17. APPENDIX: LIST OF COMPANIES AND RESEARCH ORGANIZATIONS

List of Figures

  • Figure 3.1 Classification of Advanced Therapy Medicinal Products
  • Figure 3.2 Cell Therapy Manufacturing: Key Steps
  • Figure 3.3 Cell Therapy: Challenges and Drivers
  • Figure 3.4 Cell Therapy Manufacturing: Types of Manufacturers
  • Figure 3.5 Cell-based Therapies: Potency as Critical Quality Attribute
  • Figure 4.1 Cell Therapy Manufacturing: Distribution by Location of Manufacturing Facility (Regions)
  • Figure 4.2 Cell Therapy Manufacturing: Distribution by Location of Manufacturing Facility (Countries)
  • Figure 4.3 Cell Therapy Manufacturing: Distribution by Type of Organization
  • Figure 4.4 Cell Therapy Manufacturing: Distribution by Location of Manufacturing Facility, World Map Representation
  • Figure 4.5 Cell Therapy Manufacturing: Distribution by Type of Cell Therapy
  • Figure 4.6 Cell Therapy Manufacturing: Distribution by Purpose of Production
  • Figure 4.7 Cell Therapy Manufacturing: Distribution by Scale of Operation
  • Figure 4.8 Cell Therapy Manufacturing: Distribution by Source of Cells
  • Figure 5.1 Cell Therapy Manufacturing: Roadmap for the US
  • Figure 5.2 Cell Therapy Manufacturing: Roadmap for the APEC
  • Figure 6.1 Argos Therapeutics: Revenues, 2012 - Q1-Q3 2016 (USD Million)
  • Figure 6.2 Argos Therapeutics: Funding Instances (USD Million)
  • Figure 6.3 Bavarian Nordic: Revenues, 2012- Q1-Q3 2016 (DKK Million)
  • Figure 6.4 Cytori Therapeutics: Revenues, 2012- Q1-Q3 2016 (USD Million)
  • Figure 6.5 Juno Therapeutics: Funding Instances (USD Million)
  • Figure 6.6 MEDIPOST: Revenues, 2012-2015 (KRW Billion)
  • Figure 6.7 MEDIPOST: Revenues, Distribution by Business Segments, 2015 (KRW Billion)
  • Figure 6.8 PPF Group: Revenues, 2011-2015 (EUR Billion)
  • Figure 7.1 Cell and Gene Therapy Catapult: Service Portfolio
  • Figure 7.2 CELLforCURE: Service Portfolio
  • Figure 7.3 Lonza: Historical Timeline
  • Figure 7.4 Lonza: Sub-Segments
  • Figure 7.5 Lonza Pharma and Biotech: Service Portfolio
  • Figure 7.6 Lonza: Biological Manufacturing Services
  • Figure 7.7 Lonza: Cellular Products
  • Figure 7.8 PharmaCell: Service Portfolio
  • Figure 7.9 PCT: Company Structure
  • Figure 7.10 PCT: Service Portfolio
  • Figure 7.11 Roslin Cell Therapies: Service Portfolio
  • Figure 7.12 Waisman Biomanufacturing: Service Portfolio
  • Figure 7.13 Waisman Biomanufacturing: Clinical Products Portfolio
  • Figure 7.14 Waisman Biomanufacturing: Quality Assurance and Control
  • Figure 7.15 Waisman Biomanufacturing: Manufacturing Suites
  • Figure 7.16 Waisman Biomanufacturing: Overview of Suite Services
  • Figure 8.1 Center for Cell and Gene Therapy: Operating Segments
  • Figure 8.2 Center for Cell and Gene Therapy: Service Portfolio
  • Figure 8.3 Center for Cell Manufacturing Ireland: Service Portfolio
  • Figure 8.4 Newcastle Cellular Therapies: Service Portfolio
  • Figure 10.1 Cell Therapy Manufacturing: Cumulative Trend of Collaborations (2011-2017)
  • Figure 10.2 Cell Therapy Manufacturing: Distribution by Type of Collaboration
  • Figure 10.3 Cell Therapy Manufacturing: Leading Players by Collaborations
  • Figure 11.1 Cell Therapy Manufacturing Market, 2017-2027 (USD Million)
  • Figure 11.2 Cell Therapy Manufacturing Market, 2017-2027: Distribution by Type of Cell Therapy (USD Million)
  • Figure 11.3 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2017, 2022 and 2027
  • Figure 11.4 Cell Therapy Manufacturing Market, 2017-2027: Distribution by Source of Cells (USD Million)
  • Figure 11.5 Cell Therapy Manufacturing Market, 2017-2027: Distribution by Purpose of Manufacturing
  • Figure 11.6 Cell Therapy Manufacturing Market, 2017-2027: Regional Distribution (USD Million)
  • Figure 11.7 Cell Therapy Manufacturing Market: Regional Distribution, 2017, 2022 and 2027
  • Figure 12.1 Number of Clinical Trials of Cell-based Therapies: Distribution by Cell Type
  • Figure 12.2 Number of Clinical Trials of Cell-based Therapies: Distribution by Phase of Development
  • Figure 13.1 Cell Therapy Manufacturing: Regional Distribution by Location of Manufacturing Facility, World Map Representation
  • Figure 13.2 Cell Therapy Manufacturing Market Forecast: Conservative, Base and Optimistic Scenarios, 2017-2027 (USD Million)
  • Figure 14.1 Survey Analysis: Distribution by Type of Organization
  • Figure 14.2 Survey Analysis: Distribution by Location of Manufacturing Facility
  • Figure 14.3 Survey Analysis: Distribution by Seniority Level of Respondents
  • Figure 14.4 Survey Analysis: Distribution by Type of Cell Therapy
  • Figure 14.5 Survey Analysis: Distribution by Scale of Manufacturing
  • Figure 14.6 Survey Analysis: Distribution by Source of Cells
  • Figure 14.7 Survey Analysis: Distribution by Cell Culture System
  • Figure 14.8 Survey Analysis: Distribution by Fill / Finish Service

List of Tables

  • Table 3.1 Cell-based Therapies: Applications
  • Table 3.2 Differences between Cell Therapy and Biotechnology Products
  • Table 3.3 Cell-based Therapies: Commercialized Products
  • Table 3.4 Cell Therapy Manufacturing: Assessment Strategies for Different Manufacturing Processes
  • Table 3.5 Cell-based Therapies: Regulatory Considerations
  • Table 4.1 Cell Therapy Manufacturing: List of Manufacturers
  • Table 4.2 Cell Therapy Manufacturers: Type of Cell Therapy
  • Table 4.3 Cell Therapy Manufacturers: Type of Organization and Purpose of Production
  • Table 4.4 Cell Therapy Manufacturers: Scale of Operation
  • Table 4.5 Cell Therapy Manufacturers: Source of Cells
  • Table 4.6 Logistic Service Providers for Cell-based Therapies
  • Table 5.1 Cell Processing: Challenges and Strategies
  • Table 5.2 Cell Preservation, Distribution and Handling: Challenges and Strategies
  • Table 5.3 Process Monitoring and Quality Control: Challenges and Strategies
  • Table 5.4 Standardization and Regulatory Support: Challenges and Strategies
  • Table 5.5 Workforce Development: Challenges and Strategies
  • Table 6.1 Argos Therapeutics: Company Overview
  • Table 6.2 Argos Therapeutics: Product Portfolio
  • Table 6.3 Bavarian Nordic: Company Overview
  • Table 6.4 Bavarian Nordic: Product Portfolio
  • Table 6.5 Cytori Therapeutics: Company Overview
  • Table 6.6 Cytori Therapeutics: Product Portfolio
  • Table 6.7 Juno Therapeutics: Company Overview
  • Table 6.8 Juno Therapeutics: Product Portfolio
  • Table 6.9 MEDIPOST: Company Overview
  • Table 6.10 MEDIPOST: Product Portfolio
  • Table 6.11 SOTIO: Company Overview
  • Table 6.12 SOTIO: Product Portfolio
  • Table 6.13 Stemedica Cell Technologies: Company Overview
  • Table 6.14 Stemedica Cell Technologies: Product Portfolio
  • Table 7.1 Cell and Gene Therapy Catapult: Company Overview
  • Table 7.2 Cell and Gene Therapy Catapult: Overview Manufacturing of Capabilities
  • Table 7.3 Cell and Gene Therapy Catapult: Partnerships
  • Table 7.4 CELLforCURE: Company Overview
  • Table 7.5 CELLforCURE: Overview Manufacturing of Capabilities
  • Table 7.6 CELLforCURE: Partnerships
  • Table 7.7 Lonza: Company Overview
  • Table 7.8 Lonza: Global Manufacturing Sites
  • Table 7.9 Lonza: Overview Manufacturing of Capabilities
  • Table 7.10 Lonza: Partnerships
  • Table 7.11 PharmaCell: Company Overview
  • Table 7.12 PharmaCell: Overview Manufacturing of Capabilities
  • Table 7.13 PharmaCell: Partnerships
  • Table 7.14 PCT: Company Overview
  • Table 7.15 PCT: Overview Manufacturing of Capabilities
  • Table 7.16 PCT: Partnerships
  • Table 7.17 Roslin Cell Therapies: Company Overview
  • Table 7.18 Roslin Cell Therapies: Overview Manufacturing of Capabilities
  • Table 7.19 Roslin Cell Therapies: Partnerships
  • Table 7.20 Waisman Biomanufacturing: Company Overview
  • Table 7.21 Waisman Biomanufacturing: Overview Manufacturing of Capabilities
  • Table 7.22 Waisman Biomanufacturing: Partnerships
  • Table 8.1 Center for Cell and Gene Therapy: Overview of Capabilities
  • Table 8.2 Center for Cell Manufacturing Ireland: Overview of Capabilities
  • Table 8.3 Clinical Cell and Vaccine Production Facility: Overview of Capabilities
  • Table 8.4 Guy's and St Thomas: Overview of Capabilities
  • Table 8.5 Newcastle Cellular Therapies Facility: Overview of Capabilities
  • Table 8.6 Rayne Cell Therapy Suite: Overview of Capabilities
  • Table 8.7 Scottish National Blood Transfusion Services: Overview of Capabilities
  • Table 8.8 Laboratory of Cell and Gene Medicine: Overview of Capabilities
  • Table 9.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
  • Table 9.2 CellCAN: Overview
  • Table 9.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
  • Table 9.4 National Cell Manufacturing Consortium: Overview
  • Table 9.5 California Institute of Regenerative Medicine: Overview
  • Table 9.6 Cell Therapy Manufacturing: List of Gene and Cell Therapy Societies
  • Table 10.1 Cell Therapy Manufacturing: Collaborations,
  • Table 11.1 Cell Therapies: Market Evolution
  • Table 12.1 Cell Therapy Manufacturing: SWOT Analysis
  • Table 14.1 Survey Response: Overview of the Participating Companies / Organizations
  • Table 14.2 Survey Response: Seniority Level of Respondents
  • Table 14.3 Survey Response: Type of Cell Therapy
  • Table 14.4 Survey Response: Scale of Manufacturing
  • Table 14.5 Survey Response: Source of Cells
  • Table 14.6 Survey Response: Cell Culture System
  • Table 14.7 Survey Response: Fill / Finish Service
  • Table 16.1 Cell Therapy Manufacturing: Distribution by Location of Manufacturing Facility (Regions)
  • Table 16.2 Cell Therapy Manufacturing: Distribution by Location of Manufacturing Facility (Countries)
  • Table 16.3 Cell Therapy Manufacturing: Distribution by Type of Organization
  • Table 16.4 Cell Therapy Manufacturing: Distribution by Type of Cell Therapy
  • Table 16.5 Cell Therapy Manufacturing: Distribution by Purpose of Production
  • Table 16.6 Cell Therapy Manufacturing: Distribution by Scale of Operation
  • Table 16.7 Cell Therapy Manufacturing: Distribution by Source of Cells
  • Table 16.8 Argos Therapeutics: Revenues, 2012 - Q1-Q3 2016 (USD Million)
  • Table 16.9 Argos Therapeutics: Funding Instances (USD Million)
  • Table 16.10 Bavarian Nordic: Revenues, 2012- Q1-Q3 2016 (DKK Million)
  • Table 16.11 Cytori Therapeutics: Revenues, 2012- Q1-Q3 2016 (USD Million)
  • Table 16.12 Juno Therapeutics: Funding Instances (USD Million)
  • Table 16.13 MEDIPOST: Revenues, 2012-2015 (KRW Billion)
  • Table 16.14 MEDIPOST Revenues: Distribution by Business Segments, 2015 (KRW Billion)
  • Table 16.15 PPF Group: Revenues, 2011-2015 (EUR Billion)
  • Table 16.16 Cell Therapy Manufacturing: Cumulative Trend of Collaborations (2011-2017)
  • Table 16.17 Cell Therapy Manufacturing: Distribution by Type of Collaboration
  • Table 16.18 Cell Therapy Manufacturing: Leading Players by Collaborations
  • Table 16.19 Cell Therapy Manufacturing Market, 2017-2027 (USD Million)
  • Table 16.20 Cell Therapy Manufacturing Market, 2017-2027: Distribution by Type of Cell Therapy (USD Million)
  • Table 16.21 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2017, 2022 and 2027
  • Table 16.22 Cell Therapy Manufacturing Market, 2017-2027: Distribution by Source of Cell Therapy (USD Million)
  • Table 16.23 Cell Therapy Manufacturing Market, 2017-2027: Distribution by Purpose of Manufacturing (USD Million)
  • Table 16.24 Cell Therapy Manufacturing Market, 2017-2027: Regional Distribution (USD Million)
  • Table 16.25 Cell Therapy Manufacturing Market: Regional Distribution, 2017, 2022 and 2027
  • Table 16.26 Number of Clinical Trials of Cell-based Therapies Distribution by Cell Type
  • Table 16.27 Number of Clinical Trials of Cell-based Therapies: Distribution by Phase of Development
  • Table 16.28 Cell Therapy Manufacturing Market Forecast: Conservative, Base and Optimistic Scenarios, 2017-2027 (USD Million)
  • Table 16.29 Survey Analysis: Distribution by Type of Organization
  • Table 16.30 Survey Analysis: Distribution by Location of Manufacturing Facility
  • Table 16.31 Survey Analysis: Distribution by Seniority Level of Respondents
  • Table 16.32 Survey Analysis: Distribution by Type of Cell Therapy
  • Table 16.33 Survey Analysis: Distribution by Scale of Manufacturing-
  • Table 16.34 Survey Analysis: Distribution by Source of Cells
  • Table 16.35 Survey Analysis: Distribution by Cell Culture System
  • Table 16.36 Survey Analysis: Distribution by Fill / Finish Service

Listed of Companies

The following companies and organizations have been mentioned in the report.

  • 1. 3P Biopharmaceuticals
  • 2. A2 Healthcare
  • 3. Abramson Cancer Center
  • 4. Adaptimmune
  • 5. Adicet Bio
  • 6. Advanced Manufacturing Technologies (AMTech)
  • 7. Alberta Cell Therapy Manufacturing
  • 8. Allele Biotechnology and Pharmaceuticals
  • 9. Alliance for Regenerative Medicine
  • 10. AlloSource
  • 11. Altor BioScience
  • 12. American Society of Gene and Cell Therapy
  • 13. Americans for Cures
  • 14. Amsterdam Biotherapeutics Unit (AmBTU)
  • 15. Angiocrine Bioscience
  • 16. Anterogen
  • 17. apceth Biopharma
  • 18. Argos Therapeutics
  • 19. Asahi Glass
  • 20. Asia-Pacific Economic Cooperation
  • 21. Asterias Biotherapeutics
  • 22. Asymptote
  • 23. Athersys
  • 24. Atlantic Bio GMP
  • 25. ATMI Life Sciences
  • 26. Australasian Gene and Cell Therapy Society
  • 27. Austrian Network for Gene Therapy
  • 28. AUSTRIANOVA
  • 29. Autolus
  • 30. Azellon Cell Therapeutics
  • 31. Batavia Biosciences
  • 32. Bavarian Nordic
  • 33. Bellicum Pharmaceuticals
  • 34. Bio Elpida
  • 35. BioLife Solutions
  • 36. Biological and Cellular GMP Manufacturing Facility, City of Hope
  • 37. biologistex
  • 38. Biomedical Research Centre (BRC)
  • 39. Biosafe Group
  • 40. bluebird bio
  • 41. Bone Therapeutics
  • 42. Brammer Bio
  • 43. Bristol-Myers Squibb
  • 44. British Society of Gene Therapy
  • 45. California Institute of Regenerative Medicine
  • 46. Cancer Research Technology
  • 47. Cancer Research UK, Biotherapeutics Development Unit (BDU)
  • 48. Capricor Therapeutics
  • 49. CardioCell
  • 50. Carina Biotech
  • 51. Celgene Cell Therapy
  • 52. Cell and Gene Therapy Catapult
  • 53. Cell Medica
  • 54. Cell Therapies
  • 55. Cell Therapy and Regenerative Medicine, University of Utah
  • 56. Cell Therapy Facility, University Medical Center (UMC), Utrecht
  • 57. Cell Therapy Manufacturing Cooperative Research Center
  • 58. Cell Therapy Suit (CTS), University of Birmingham
  • 59. CellCAN
  • 60. Cellectis
  • 61. CELLforCURE
  • 62. Cellin Technologies
  • 63. Cells Cure Foundation
  • 64. Cells for Sight, Stem Cell Therapy Research Unit, University College London
  • 65. Cellular Biomedicine Group (CBMG)
  • 66. Cellular Dynamics International (a FUJIFILM company)
  • 67. Cellular Therapeutics
  • 68. Cellular Therapy Integrated Services (CTIS), Case Western Reserve University
  • 69. Celyad (formerly known as Cardio3 BioSciences)
  • 70. Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
  • 71. Center for Cell and Gene Therapy, Baylor College of Medicine
  • 72. Center for Commercialization of Regenerative Medicine (CCRM)
  • 73. Center for Gene and Cell Processing (CGCP), Takara Bio
  • 74. Center for Stem Cell Research (CSCR)
  • 75. Centre for Cell Manufacturing Ireland (CCMI), NUI Galway
  • 76. Centre Multidisciplinaire de Développement du Génie Tissulaire, Université Laval
  • 77. Centre of Genomics and Policy, McGill University
  • 78. Children's GMP / GMP Facility St. Jude Children's Research Hospital
  • 79. China National Accreditation Service
  • 80. CiMaas
  • 81. Citizens Financial Accountability Oversight Committee (CFAOC)
  • 82. Clinical Biomanufacturing Facility, University of Oxford
  • 83. Clinical Cell and Vaccine Production Facility (CVPF), University of Pennsylvania
  • 84. Clinical Research Facility, South London and Maudsley
  • 85. Cognate Bioservices
  • 86. Cook Myosite
  • 87. Cryoport
  • 88. Cryosite
  • 89. CureCell
  • 90. Cynata Therapeutics
  • 91. Cytori Therapeutics
  • 92. Dana-Farber / Harvard Cancer Center Cell Manipulation Core
  • 93. DanDrit Biotech
  • 94. Dendreon (acquired by Valeant Pharmaceuticals)
  • 95. EMD Millipore
  • 96. EUFETS
  • 97. European Bank for induced pluripotent Stem Cells
  • 98. European Society of Gene and Cell Therapy
  • 99. Fibrocell
  • 100. Finnish Gene Therapy Society
  • 101. Fisher BioServices
  • 102. Fondation de l'Hˆpital Maisonneuve-Rosemont
  • 103. Fondazione Telethon
  • 104. Foundation for the Accreditation of Cellular Therapy
  • 105. Foundation of Croatian Association for Regenerative Medicine and Stem Cell Therapy
  • 106. Fraunhofer Institute for Cell Therapy and Immunology IZI
  • 107. Fraunhofer Institute for Interfacial Engineering and Biotechnology
  • 108. Fred Hutchinson Cancer Research Center
  • 109. French Society of Cellular and Gene Therapy
  • 110. Gates Biomanufactuirng Facility
  • 111. GE Global Research
  • 112. GE Healthcare
  • 113. GE Ventures
  • 114. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  • 115. Gene Therapy and Radiation Research Foundation
  • 116. Genenta Science
  • 117. Georgia Institute of Technology
  • 118. Georgia Research Alliance
  • 119. German Gene Therapy Society
  • 120. German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen (GRCBDS)
  • 121. GlaxoSmithKline
  • 122. Gradalis
  • 123. Great Ormond Street Hospital (GOSH) Cellular Therapy Laboratories, University College London
  • 124. Green Cross
  • 125. Guy's and St Thomas' Facility
  • 126. Health Industries South Australia
  • 127. Health Sciences Authority, Singapore
  • 128. Hielscher Ultrasonics
  • 129. Histocell
  • 130. Hitachi Chemicals
  • 131. Hitachi PCT
  • 132. Hospital of University of Pennsylvania
  • 133. Houston Methodist Hospital
  • 134. Houston Methodist Hospital Foundation
  • 135. Houston Methodist Research Institute
  • 136. Immatics Biotechnologies
  • 137. ImmunoCellular Therapeutics
  • 138. Immunocore
  • 139. Immunovative Therapies
  • 140. Innovate UK
  • 141. Institute of Cellular Medicine
  • 142. IntelliCell BioSciences
  • 143. Intercytex
  • 144. International Cellular Medicine Society
  • 145. International Society for Cancer Gene Therapy
  • 146. International Society for Cellular Therapy
  • 147. International Society for Stem Cell Research
  • 148. Invetech
  • 149. iPS Academia Japan
  • 150. Irish Society for Gene and Cell Therapy
  • 151. Irish Stem Cell Foundation
  • 152. Islet Sciences
  • 153. Israeli Society for Gene and Cell Therapy
  • 154. Janssen
  • 155. Japan Society for Gene Therapy
  • 156. Japan Tissue Engineering
  • 157. JingYuan Bio
  • 158. John Goldmann Centre for Cellular Therapy, Imperial College London
  • 159. Juno Therapeutics
  • 160. JW Biotechnology
  • 161. JW CreaGene
  • 162. KBI Biopharma
  • 163. Kiadis Pharma
  • 164. King's College London
  • 165. Kite Pharma
  • 166. Korean Society of Gene and Cell Therapy
  • 167. Kyoto University
  • 168. Laboratory of Cell and Gene Medicine, Stanford University
  • 169. Life Technologies
  • 170. Lion Biotechnologies
  • 171. Lonza
  • 172. Loughborough University
  • 173. Lummy HK
  • 174. Marken
  • 175. MassBio
  • 176. MaSTherCell
  • 177. Mayo Clinic
  • 178. MED REBELS
  • 179. MedCision
  • 180. Medigene
  • 181. Medinet
  • 182. Medipost
  • 183. Merix Bioscience
  • 184. Mesoblast
  • 185. Michael G Harris Cell Therapy and Cell Engineering Facility (CTCEF), Memorial Sloan Kettering Cancer Center
  • 186. Michael Smith Laboratories, University of British Columbia
  • 187. Milentyi Biotec
  • 188. MNX Global Logistics
  • 189. Molecular and Cellular Therapeutics, University of Minnesota
  • 190. MolMed
  • 191. MRC Centre for Regenerative Medicine,University of Edinburgh
  • 192. Nantes University Hospital
  • 193. National Cancer Institute (NCI)
  • 194. National Cell Manufacturing Consortium
  • 195. National Institute of Health Center of Regenerative Health
  • 196. National Institute of Standards and Technologies
  • 197. National Stem Cell Foundation
  • 198. National Stem Cell Foundation of Australia
  • 199. National University of Ireland (NUI), Galway
  • 200. Netherlands Cancer Institute
  • 201. Networks of Centres of Excellence (NCE) of Canada
  • 202. Neuralstem
  • 203. Newcastle Cellular Therapies Facility, Newcastle University
  • 204. NewLink Genetics
  • 205. NextCell
  • 206. NHS Blood and Transplant
  • 207. NHS Blood and Transplant Birmingham
  • 208. Nikon
  • 209. Nikon Cell and Gene Therapy Contract Manufacturing
  • 210. North Carolina State University
  • 211. Northwest Biotherapeutics
  • 212. Novartis
  • 213. Novo Nordisk Engineering (NNE)
  • 214. NuVasive
  • 215. Ocata Therapeutics
  • 216. Octane
  • 217. Oncobiomed
  • 218. Ontario Institute of Regenerative Medicine
  • 219. Orbsen Therapeutics
  • 220. Orchard Therapeutics
  • 221. Orthofix
  • 222. Osiris Therapeutics
  • 223. Ottawa Hospital Research Institute
  • 224. Oxford BioMedica
  • 225. Pall Corporation
  • 226. PAREXEL
  • 227. PCI Services (Biotec Services International)
  • 228. PCT, a Caladrius Company
  • 229. Peter Couche Foundation
  • 230. Peter MacCallum Cancer Center
  • 231. Pfizer
  • 232. PharmaBio
  • 233. PharmaCell
  • 234. Pharmicell
  • 235. Pharmstandard
  • 236. Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
  • 237. Pluristem Therapeutics
  • 238. PPF Group
  • 239. Production Assistance for Cellular Therapies
  • 240. Promethera Biosciences
  • 241. Raymond G Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia
  • 242. Rayne's Cell Therapy Suite, King's College London
  • 243. Regenerative Medicine Foundation
  • 244. Regenerative Medicine Institute
  • 245. Regeneus
  • 246. Reinnervate
  • 247. Reliance Life Sciences
  • 248. ReNeuron
  • 249. Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
  • 250. Riyadh Pharma
  • 251. Robertson Clinical and Translational Cell Therapy, Duke University
  • 252. Roche Diagnostics
  • 253. Rockefeller University
  • 254. RoosterBio
  • 255. Roslin Cells
  • 256. Roswell Park Cancer Institute
  • 257. Royal Adelaide Hospital
  • 258. Royal Free, CCGTT
  • 259. Royal Prince Alfred Hospital
  • 260. Royal Victoria Infirmary
  • 261. Saint-Gobain
  • 262. SAVSU Technologies
  • 263. Science Foundation Ireland
  • 264. Scottish Centre for Regenerative Medicine
  • 265. Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy
  • 266. Seattle Children's Research Institute
  • 267. Servier
  • 268. Sistemic
  • 269. Smilow Translational Research Center
  • 270. Smith & Nephew
  • 271. SOTIO
  • 272. South London and Maudsley Foundation Trust
  • 273. Spanish Society of Gene and Cell Therapy
  • 274. Stage Cell Therapeutics
  • 275. Stem Cell Institute
  • 276. StemCutis
  • 277. Stemedica Cell Technologies
  • 278. Stemedica International
  • 279. StemedicaAsia
  • 280. StemProtein
  • 281. Swedish Society for Gene and Cell Therapy
  • 282. Sydney Cell and Gene Therapy
  • 283. Synpromics
  • 284. TAP Biosystems
  • 285. TargetAMD
  • 286. TC Biopharma
  • 287. Terumo BCT
  • 288. Texas Children's Hospital
  • 289. The Canadian Gene Cure Foundation
  • 290. The Houston Methodist Institute of Technology
  • 291. The Netherlands Society of Gene and Cell Therapy
  • 292. The New York Stem Cell Foundation
  • 293. Therapeutic Cell Production Core (TCPC), Seattle Children's Hospital
  • 294. TiGenix
  • 295. Tmunity Therapeutics
  • 296. TNK Therapeutics
  • 297. Tokyo Electron
  • 298. TrakCel
  • 299. Turkish Society for Gene and Cell Therapy
  • 300. TVAX Biomedical
  • 301. TxCell
  • 302. Tyne Hospitals NHS Foundation Trust
  • 303. UC Davis GMP Laboratory
  • 304. UCLA Human Gene and Cell Therapy
  • 305. UK Stem Cell Foundation
  • 306. University Hospital South Manchester NHS Foundation Trust (UHSM)
  • 307. University of California
  • 308. University of Cambridge
  • 309. University of Leeds
  • 310. University of Manchester
  • 311. University of Texas
  • 312. University of Wollongong
  • 313. Upstate Stem Cell cGMP Facility, University of Rochester
  • 314. Vaccinogen
  • 315. Vecura, Karolinska University Hospital
  • 316. Vericel
  • 317. Vitruvian Networks
  • 318. Vor Biopharma
  • 319. Waisman Biomanufacturing
  • 320. World Courier
  • 321. WuXi AppTec
  • 322. Xellbiogene
  • 323. YposKesi
Back to Top